Precision NanoSystems Announces Collaboration Agreement with Evonik Canada for the Manufacturing of Nanomedicines
Product News Jun 01, 2018
The NanoAssmblr™Platform a Solution at Every Stage
Precision Nanosystems Inc. (PNI), announced that they have entered into a manufacturing collaboration agreement with Evonik Canada for the tech transfer of the NanoAssemblr Scale-Up system to Evonik Vancouver Laboratories (VAN) for the manufacture of high quality nanomedicines, for late stage clinical research. This agreement builds on a successful initial partnership between Evonik and PNI where the NanoAssemblr Scale-Up system and related processes were transferred between the R&D teams.
PNI and Evonik will also establish a demonstration area to showcase the NanoAssemblr suite of products in Darmstadt, Germany. This facility will be used for performing hands-on demonstrations, seminars, workshops and training programs for potential customers.
Evonik Vancouver Laboratories is a Contract Development and Manufacturing Organization (CDMO) that provides formulation and development services as well as products to biotechnology companies engaged in the development of pharmaceutical products. "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr Scale-Up platform, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use," said Don Enns, Vice President of Evonik Vancouver Laboratories.
The system transferred into VAN comprises eight of the microfluidic mixers plumbed in a parallel configuration to enable up to 25L batches with higher volumes possible though additional parallelization. As part of the manufacturing collaboration agreement, Evonik and PNI will work together to support customers in the formulation, scale up and GMP manufacturing of nanomedicines.
"We are very pleased to announce our collaboration with Evonik as it exemplifies our goal to build the NanoAssemblr platform for the seamless scale up from discovery to GMP manufacturing of the next generation nanomedicines," said James Taylor, CEO & Co-Founder PNI.